A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes.
Vicki J SwierKatherine A WhiteTyler B JohnsonJessica C SierenHans J JohnsonKevin KnoernschildXiaojun WangFrank A RohretChristopher S RogersDavid A PearceJon J BrudvigJill M WeimerPublished in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2022)
CLN2 Batten disease is a lysosomal disorder in which pathogenic variants in CLN2 lead to reduced activity in the enzyme tripeptidyl peptidase 1. The disease typically manifests around 2 to 4 years of age with developmental delay, ataxia, seizures, inability to speak and walk, and fatality between 6 and 12 years of age. Multiple Cln2 mouse models exist to better understand the etiology of the disease; however, these models are unable to adequately recapitulate the disease due to differences in anatomy and physiology, limiting their utility for therapeutic testing. Here, we describe a new CLN2 R208X/R208X porcine model of CLN2 disease. We present comprehensive characterization showing behavioral, pathological, and visual phenotypes that recapitulate those seen in CLN2 patients. CLN2 R208X/R208X miniswine present with gait abnormalities at 6 months of age, ERG waveform declines at 6-9 months, vision loss at 11 months, cognitive declines at 12 months, seizures by 15 months, and early death at 18 months due to failure to thrive. CLN2 R208X/R208X miniswine also showed classic storage material accumulation and glial activation in the brain at 6 months, and cortical atrophy at 12 months. Thus, the CLN2 R208X/R208X miniswine model is a valuable resource for biomarker discovery and therapeutic development in CLN2 disease.